Financial Performance - Lexeo Therapeutics reported a net loss of 0.78 per share for Q4 2024, compared to a net loss of 0.86 per share for Q4 2023 [10]. - For the full year 2024, the net loss was 3.09 per share, compared to a net loss of 12.40 per share for 2023 [10]. - General and administrative expenses rose to 6.8 million in Q4 2023, with total expenses for the year reaching 15.4 million in 2023 [10]. Research and Development - Research and development expenses increased to 8.2 million in Q4 2023, and totaled 53.1 million in 2023 [10]. - Interim update from cohort 1 of the LX2020 HEROIC-PKP2 trial showed 71% and 115% increases in PKP2 protein expression from baseline [10]. - The first participant evaluated 6 months post-treatment experienced a 67% reduction in premature ventricular contractions (PVCs), decreasing from 861 to 284 [10]. - Enrollment for cohort 2 of the LX2020 HEROIC-PKP2 trial has been completed, with interim clinical data expected in the second half of 2025 [10]. - Lexeo Therapeutics anticipates further regulatory clarity for LX2006, including the inclusion of pediatric cohorts in the planned pivotal study [10]. Cash Position - Cash, cash equivalents, and investments as of December 31, 2024, were $128.5 million, expected to fund operations into 2027 [10]. Regulatory Developments - The European Commission granted orphan medicinal product designation for LX2020 for the treatment of PKP2-ACM in March 2025 [10].
Lexeo Therapeutics(LXEO) - 2024 Q4 - Annual Results